Antyra, Novo Nordisk deal

Antyra (formerly DGI Biotechnologies Inc.) received exclusive, worldwide rights from Novo Nordisk to develop and commercialize insulin-like growth factor (IGF) antagonists. Antyra plans to begin Phase...